Table 2 Exposure analysis
Experimental group (N = 39) | Control group (N = 18) | |
|---|---|---|
First cycle | ||
Paclitaxel amount (mg) | ||
Median (Q1,Q3) | 235.00 (220.00, 240.00) | 225.00 (210.00, 240.00) |
Mean ± SD | 231.67 ± 16.69 | 227.94 ± 24.73 |
Paclitaxel dose (mg/m2) | ||
Median (Q1,Q3) | 150.07 (149.34, 151.90) | 149.33 (144.83, 150.00) |
Mean ± SD | 150.91 ± 7.26 | 146.78 ± 6.68 |
Cisplatin amount (mg) | ||
Median (Q1,Q3) | 106.00 (100.00, 110.00) | 100.00 (100.00, 110.00) |
Mean ± SD | 105.66 ± 9.70 | 102.89 ± 9.68 |
Cisplatin dose (mg/m2) | ||
Median (Q1,Q3) | 69.18 (67.11, 70.51) | 68.49 (66.12, 69.18) |
Mean ± SD | 68.73 ± 3.44 | 66.47 ± 5.14 |
Second cycle | ||
Whether to adjust the dose in the second cycle | ||
Yes | 0 | 0 |
No | 39 (100.00%) | 18 (100.00%) |
Whether to remedy the use of short-acting rhG-CSF | ||
Yes | 3 (7.69%) | 18 (100.00%) |
No | 36 (92.31%) | 0 |